313 related articles for article (PubMed ID: 31704173)
1. Dichotomous Sirtuins: Implications for Drug Discovery in Neurodegenerative and Cardiometabolic Diseases.
Gomes P; Leal H; Mendes AF; Reis F; Cavadas C
Trends Pharmacol Sci; 2019 Dec; 40(12):1021-1039. PubMed ID: 31704173
[TBL] [Abstract][Full Text] [Related]
2. Sirtuins as possible targets in neurodegenerative diseases.
Donmez G
Curr Drug Targets; 2013 Jun; 14(6):644-7. PubMed ID: 23410123
[TBL] [Abstract][Full Text] [Related]
3. Sirtuin modulators: targets for metabolic diseases and beyond.
Szczepankiewicz BG; Ng PY
Curr Top Med Chem; 2008; 8(17):1533-44. PubMed ID: 19075764
[TBL] [Abstract][Full Text] [Related]
4. Sirtuin modulators: mechanisms and potential clinical implications.
Sanchez-Fidalgo S; Villegas I; Sanchez-Hidalgo M; de la Lastra CA
Curr Med Chem; 2012; 19(15):2414-41. PubMed ID: 22455589
[TBL] [Abstract][Full Text] [Related]
5. SIRTUIN 1: regulating the regulator.
Zschoernig B; Mahlknecht U
Biochem Biophys Res Commun; 2008 Nov; 376(2):251-5. PubMed ID: 18774777
[TBL] [Abstract][Full Text] [Related]
6. Sirtuin-targeting drugs: Mechanisms of action and potential therapeutic applications.
Aljada A; Dong L; Mousa SA
Curr Opin Investig Drugs; 2010 Oct; 11(10):1158-68. PubMed ID: 20872319
[TBL] [Abstract][Full Text] [Related]
7. Seven sirtuins for seven deadly diseases of aging.
Morris BJ
Free Radic Biol Med; 2013 Mar; 56():133-71. PubMed ID: 23104101
[TBL] [Abstract][Full Text] [Related]
8. The neurobiology of sirtuins and their role in neurodegeneration.
Donmez G
Trends Pharmacol Sci; 2012 Sep; 33(9):494-501. PubMed ID: 22749331
[TBL] [Abstract][Full Text] [Related]
9. Sirtuins and NAD
Kane AE; Sinclair DA
Circ Res; 2018 Sep; 123(7):868-885. PubMed ID: 30355082
[TBL] [Abstract][Full Text] [Related]
10. Sirtuins and Their Implications in Neurodegenerative Diseases from a Drug Discovery Perspective.
Yeong KY; Berdigaliyev N; Chang Y
ACS Chem Neurosci; 2020 Dec; 11(24):4073-4091. PubMed ID: 33280374
[TBL] [Abstract][Full Text] [Related]
11. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders.
Huber K; Superti-Furga G
Bioorg Med Chem; 2011 Jun; 19(12):3616-24. PubMed ID: 21306906
[TBL] [Abstract][Full Text] [Related]
12. Biology, Chemistry, and Pharmacology of Sirtuins.
Bedalov A; Chowdhury S; Simon JA
Methods Enzymol; 2016; 574():183-211. PubMed ID: 27423863
[TBL] [Abstract][Full Text] [Related]
13. Evidence supporting a mechanistic role of sirtuins in mood and metabolic disorders.
Alageel A; Tomasi J; Tersigni C; Brietzke E; Zuckerman H; Subramaniapillai M; Lee Y; Iacobucci M; Rosenblat JD; Mansur RB; McIntyre RS
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():95-101. PubMed ID: 29802856
[TBL] [Abstract][Full Text] [Related]
14. New assays and approaches for discovery and design of Sirtuin modulators.
Schutkowski M; Fischer F; Roessler C; Steegborn C
Expert Opin Drug Discov; 2014 Feb; 9(2):183-99. PubMed ID: 24382304
[TBL] [Abstract][Full Text] [Related]
15. Using mitochondrial sirtuins as drug targets: disease implications and available compounds.
Gertz M; Steegborn C
Cell Mol Life Sci; 2016 Aug; 73(15):2871-96. PubMed ID: 27007507
[TBL] [Abstract][Full Text] [Related]
16. Sirtuin activators and inhibitors: Promises, achievements, and challenges.
Dai H; Sinclair DA; Ellis JL; Steegborn C
Pharmacol Ther; 2018 Aug; 188():140-154. PubMed ID: 29577959
[TBL] [Abstract][Full Text] [Related]
17. The sirtuin family's role in aging and age-associated pathologies.
Hall JA; Dominy JE; Lee Y; Puigserver P
J Clin Invest; 2013 Mar; 123(3):973-9. PubMed ID: 23454760
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of activators and inhibitors of sirtuins.
Balcerczyk A; Pirola L
Biofactors; 2010; 36(5):383-93. PubMed ID: 20848588
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial Sirtuins and Molecular Mechanisms of Aging.
van de Ven RAH; Santos D; Haigis MC
Trends Mol Med; 2017 Apr; 23(4):320-331. PubMed ID: 28285806
[TBL] [Abstract][Full Text] [Related]
20. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases.
Imai S; Guarente L
Trends Pharmacol Sci; 2010 May; 31(5):212-20. PubMed ID: 20226541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
